Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Cyclophosphamide (CTX)

9 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCPED15143

    02/15/2017

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory Bprecursor Acute Lymphoblastic Leukemia (r/r ALL)

    Treatment

    VICCBMT15150

    01/10/2017

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

    Treatment

    VICCBMT1652

    09/30/2016

    VICCBMT1652 - A Phase 1, Multicenter, Open-Label, Dose-Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion with Subcutaneous Recombinant Human IL-2 (RHIL- 2) in Adults with Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

    Treatment

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    COGAHOD1331

    07/15/2015

    A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

    Treatment

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Treatment

    VICCNCPED1414

    04/24/2014

    HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus

    Treatment

    VICCNCBMT12108

    05/08/2013

    A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies

    Treatment

    VICCHEM1146

    08/14/2012

    Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lymphoma


    Print this page for your doctor